A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment
Crossref DOI link: https://doi.org/10.1007/s43440-024-00629-x
Published Online: 2024-08-02
Published Print: 2024-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tobaiqy, Mansour http://orcid.org/0000-0002-4292-0900
Text and Data Mining valid from 2024-08-02
Version of Record valid from 2024-08-02
Article History
Received: 3 March 2024
Revised: 10 July 2024
Accepted: 11 July 2024
First Online: 2 August 2024
Declarations
:
: The author declares no conflict of interest.